Norman Wolmark
Norman Wolmark on the study’s frustrating but unequivocal results showing that bevacizumab did not extend disease-free survival in adjuvant therapy for early colon cancer at 3 years, even though there had been a benefit at 1 year. Also weighing in: Nicholas Petrelli.
LISTEN
[audio:https://www.audiomedica.com/podcasting/otbn/090914NormWomarkNiPetrelliPODCAST.mp3]
Enzalutamide improves overall and progression-free survival in men with chemotherapy-naïve metastatic castration-resistant prostate cancer 6 Mar, 2014 
ASCO Audio Journal of Oncology – August 1st 2006 30 Jul, 2006 
Gene expression and molecular pathways guide head and neck cancer therapies 24 Apr, 2013 
The WIN consortium meets in Paris – a boost for cancer science 17 Jul, 2013 
Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014